An interventional study of intracytoplasmic sperm injection and artificial oocyte activation and intracytoplasmic sperm injection in Male Infertility and Teratospermia, sponsored by ShangHai Ji Ai Genetics & IVF Institute. Recruiting at 1 site in China. Open to participants aged 20 Years to 37 Years. Per ClinicalTrials.gov, last updated 2026-02-02.
Sponsored by ShangHai Ji Ai Genetics & IVF Institute · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Infertility, Male with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Infertility, Male · China.
Among the 10 studies in Infertility, Male with a site in China, this one is the only one that started in 2024, is one of 4 with no phase, and was the 9th registered.
283 studies on the registry are indexed under Infertility, Male; 65 are open to participants now.
Browse Infertility, Male studies →3 of the 10 studies in Infertility, Male with a site in China are open now. Recruiting first, the newest first:
Zhujiang Hospital · Sites in China
Ages 18–45 · Men only · Healthy volunteers
The Third Affiliated Hospital of Guangzhou Medical University · Sites in China
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 41 Infertility, Male studies recruiting now, 17 (41%) set no upper age limit and 24 (59%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 20 Years to 37 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 208 is above the median of 80 across 188 interventional studies indexed under Infertility, Male.
Median enrollment 134 across the 6 interventional studies, 753 across the 4 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 10 has an industry lead sponsor. The 9 most frequent:
ShangHai Ji Ai Genetics & IVF Institute is the lead sponsor of 26 studies on the registry; 5 are open to participants now.
ShangHai Ji Ai Genetics & IVF Institute has 1 study filed under Infertility, Male — fewer than ten, so there is no comparison to draw.
2 of the studies in Infertility, Male with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06561451ShangHai Ji Ai Genetics & IVF InstituteLive Birth Rate Between ICSI and AOA and ICSI Alone in Patients With Severe Teratospermia | 2026-12-30 |
| NCT07691827The Third Affiliated Hospital of Guangzhou Medical UniversityMaternal Inheritance of a Pathogenic MT-ND1 Mutation Causes Mitochondrial Dysfunction and Spermatogenic Failure in Men | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Infertility, Male with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to compare the live birth rate between intracytoplasmic sperm injection (ICSI) and artificial oocyte activation (AOA) vs intracytoplasmic sperm injection alone in patients with teratospermia. The hypothesis is the live birth rate following ICSI and AOA is significantly higher than that by ICSI alone in patients with teratospermia. This is a randomized controlled trial. Participants will be randomly assigned into one of the two groups:
ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
ICSI alone group: a single sperm will be injected within 4 hours after the follicular aspiration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ICSI+AOA group: a single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
Procedure: intracytoplasmic sperm injection and artificial oocyte activation
a single sperm will be injected within 4 hours after the follicular aspiration.
Procedure: intracytoplasmic sperm injection
A single sperm will be injected within 4 hours after the follicular aspiration. All injected oocytes will be incubated in the calcium ionophore A23187 activation solution (C9275-1MG, Sigma, USA) for 10 min, and cultured in the cleavage medium (Cleavage Medium , Cook, United States) under standard conditions.
A single sperm will be injected within 4 hours after the follicular aspiration.
Live birth
Delivery ≥22 weeks of gestation with heartbeat and breath.
Time frame: 1 year after embryo transfer
Fertilization rate
Fertilized oocytes with two pronuclei per MII oocyte injected
Time frame: 1 day after oocyte retrieval
High-quality embryos on Day 3
Seven or eight blastomeres of equal-size and \<20% fragmentation by volume
Time frame: 3 days after oocyte retrieval
hCG positivity
Serum hCG level ≥10mIU/mL
Time frame: 14 days after embryo transfer
Number and grading of embryos/blastocysts
Number and grading of embryos/blastocysts suitable for freezing and transfer
Time frame: 6 days after oocyte retrieval
Clinical pregnancy
the presence of an intrauterine gestational sac on transvaginal ultrasound at 6 gestational weeks.
Time frame: 6 weeks of gestation
Ongoing pregnancy
a viable pregnancy beyond 12 weeks of gestation
Time frame: 12 weeks of gestation
Multiple pregnancy
presence of more than one intrauterine sac at 6 weeks of gestation
Time frame: 6 weeks of gestation
Cumulative live birth rate (within 6 months after randomization)
Any live birth arising from embryo transfer within 6 months after randomization
Time frame: 1.5 years after the randomization
Miscarriage rate
A clinically recognized pregnancy loss before 22 weeks of pregnancy. The denominator is the clinical pregnancy.
Time frame: 22 weeks of pregnancy
Birth weights of the newborns
Birth weights of the newborns
Time frame: 1 year after embryo transfer
Plan to share: Yes — Data from the trial will be shared according to the International Committee of Medical Journal Editors guidelines. Individual participant data that underlie the results after deidentification (text, tables, figures and appendices) and the study protocol will be shared. On request, data can be shared with parties presenting relevant aims for the use of data. Data will be available from 3 months to 5 years following article publication.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data will be available from 3 months to 5 years following article publication
Access criteria: On request, data can be shared with parties presenting relevant aims for the use of data. Please contact the researcher through email: lihe198900@163.com.
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 78 non-industry interventional studies with no phase under Infertility, Male, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's planned 28 months is close to that.
Counting every sponsor, half of 93 studies reached it within 34 months; a quarter within 17 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
ShangHai Ji Ai Genetics & IVF Institute